Marcus‐Hillert Schultze‐Mosgau
Bayer (Germany)(DE)
Publications by Year
Research Areas
Uterine Myomas and Treatments, Endometriosis Research and Treatment, Estrogen and related hormone effects, Pharmacogenetics and Drug Metabolism, Gynecological conditions and treatments
Most-Cited Works
- → Cytochrome P450 dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative(1993)65 cited
- → Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women(2016)43 cited
- → Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies(2018)31 cited
- → Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial(2016)31 cited
- → Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential(2018)29 cited
- → Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women(2017)26 cited
- → Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women(2016)25 cited
- → CYP3A4‐mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1‐mediated effects on bilirubin glucuronidation in humans(2018)22 cited
- → The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension(2017)22 cited
- → Model‐Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms(2016)22 cited